Cabergoline adverse effects

Dopamine receptor agonists. Deficient dopaminergic transmission in the striatum can be compensated by ergot derivatives (bromocriptine p. 114], lisu-ride, cabergoline, and pergolide) and nonergot compounds (ropinirole, prami-pexole). These agonists stimulate dopamine receptors (D2, D3, and D sub-types), have lower clinical efficacy than levodopa, and share its main adverse effects. 

At least as effective as bromocriptine in the treatment of advanced parkinsonian patients with levodopa-related motor fluctuations adverse effects similar in incidence and severity appears to lack some of the toxicity seen with bromocriptine, pergolide, and cabergoline (e.g., pleuropulmonary disease) may be a useful alternative in patients with intolerable adverse effects due to ergot derivatives... 

Cabergoline Therapy of hyperprolactinemia Oral tablet Proved to be effective and safe, without adverse effects of oral administration 331... 

Cabergoline is an ergoline derivative that has been used in patients with hyperprolactinemia (SEDA-15,133), but is used nowadays in patients with Parkinson s disease. Its adverse effects include nausea, hjrpotension, headache. 

Cabergoline is commercially available as 0.5-mg oral tablets. The initial dose of cabergoline for the treatment of hyperprolactinemia is 0.5 mg once weekly or in divided doses twice weekly. This dose may be increased by increments of 0.5 mg at 4-week intervals based on serum prolactin concentrations. The usual dose is 1 to 2 mg weekly however, doses as high as 4.5 mg weekly have been used. Recent studies have also evaluated the efficacy of a vaginal dosage form of cabergoline to reduce the adverse effects associated with oral therapy. ... 

Cabergoline appears to be more effective than bromocriptine for the medical management of prolactinomas and offers the advantage of less-frequent dosing and decreased adverse events. 

---